Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BMS-986278 in progressive pulmonary fibrosis
jRCT2021230037Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of admilparant in pulmonary fibrosis (PF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Absolute change in forced vital capacity. Started Jan 2024; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCT2021230037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230037.